Background The potential benefit of dual antiplatelet therapy beyond 1 year after a myocardial
infarction has not been established. We investigated the efficacy and safety of ticagrelor, a …

Background In patients with type 2 diabetes, inhibitors of sodium–glucose cotransporter 2 (SGLT2)
reduce the risk of a first hospitalization for heart failure, possibly through glucose-…

Background Thrombin potently activates platelets through the protease-activated receptor
PAR-1. Vorapaxar is a novel antiplatelet agent that selectively inhibits the cellular actions of …

Background Patients with peripheral artery disease have an increased risk of cardiovascular
morbidity and mortality. Antiplatelet agents are widely used to reduce these complications. …

Background Vorapaxar is a new oral protease-activated–receptor 1 (PAR-1) antagonist that
inhibits thrombin-induced platelet activation. Methods In this multinational, double-blind, …

Background The effect of intensified platelet inhibition for patients with unstable angina or
myocardial infarction without ST-segment elevation who do not undergo revascularization has …

Background The assessment of myocardial viability has been used to identify patients with
coronary artery disease and left ventricular dysfunction in whom coronary-artery bypass …

Objectives : The purpose of this study is to evaluate the efficacy and safety of ticagrelor and
clopidogrel in patients with acute coronary syndrome undergoing coronary artery bypass …

Background The cholesteryl ester transfer protein inhibitor evacetrapib substantially raises
the high-density lipoprotein (HDL) cholesterol level, reduces the low-density lipoprotein (LDL) …

Background Coronary artery disease is a major cause of morbidity and mortality worldwide,
and is a consequence of acute thrombotic events involving activation of platelets and …